Answers are grounded in this paper and cite their sources.
Elotuzumab is a humanized immunoglobulin G1 immunostimulatory monoclonal antibody targeted against signaling lymphocytic activation molecule F7 (SLAMF7). 1 A phase 1 clinical study (NCT01241292) of elotuzumab in combination with lenalidomide and dexamethasone (ELd) in six patients with relapsed/refractory multiple myeloma (RRMM) was conducted in Japan. The study reported an acceptable safety and tolerability profile and an overall response rate of 83% (5/6). 2 ELOQUENT-2 (NCT01239797) is a phase 3, international, randomized clinical trial that investigated the efficacy and safety of ELd compared with lenalidomide/dexamethasone (Ld) in patients with RRMM who had received one to three previous therapies. 3 Patients were randomized 1:1 to ELd ( n =321) or Ld ( n =325). Asian patients comprised 10% (64/646) of the overall population, of which 94% (60/64) were enrolled from Japan.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: